Avera Pharmaceuticals Inc.
This article was originally published in Start Up
Executive SummaryAvera Pharmaceuticals Inc. is betting that there are enough promising neurological and psychiatric drugs gathering dust on the shelves of Big Pharma to support a substantial specialty business. It is starting out with a portfolio of neuromuscular blocker compounds acquired from GlaxoSmithKline PLC.
You may also be interested in...
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.